Insight Medbotics Incorporated was created by the Centre for Surgical Invention and Innovation (CSii) in partnership with MDA, builders of the iconic Canadarm, Canadarm2 and Dextre to commercially launch a new generation of intelligent robotic systems which leverage Canadian expertise in space technology and informatics for use in Image Guided Automated Robotics (IGAR). IGAR-Breast, the first such device was designed to detect and treat breast cancer in it’s earliest stages. MRI is widely regarded as the superior diagnostic imaging modality for monitoring and diagnosing women with a heightened genomic and phenomic risk of breast cancer. We are applying proprietary IP and clinical excellence to identify, biopsy, and optimally treat early stage breast cancer.

Our robotics are designed to work inside an MRI bore. The MRI suite is among the most challenging of hospital environments because the device uses strong magnetic fields and has a confined working area for physicians.

IGAR, our first robotics system, can be mounted on an MRI table and has potential applications for biopsy, therapy delivery or device placement. We're developing robotics for more targeted care everywhere.

IGAR is not currently cleared as a medical device for sale by Health Canada.

We're witnessing a new future for MRI. Technological advances in imaging, robotics and AI are making new clinical scenarios possible, making MRI more accessible for patients, radiologists and new non-radiologist users. Combined, these three areas have the potential to open greater patient access to MRI.

The IGAR technology platform may be adapted for future products that could move seamlessly across different care environments, such as from an MRI to a standard operating room or into a physician’s office.

The system has been validated in the MRI environment and demonstrated in clinical studies.

Insight Medbotics is pleased to announce that Stephen R. La Neve has joined the company’s Board of Directors.

Insight Medbotics, a medical device company combining the accuracy of MRI with the precision of robotics, is pleased to announce two appointments to the company's Clinical Advisory Board. 

Insight Medbotics is featured in the Medtech Strategist’s February 2024 issue as a 'Start-Up to Watch.' 

The IGAR system is the first and only robotic guidance and placement system cleared to work inside an MRI bore, one of the most challenging hospital environments. 

Insight Medbotics has secured a successful 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IGAR system. The clearance applies to breast biopsy indications. 

Our Management Team, Board of Directors, and Clinical Advisory Board bring expertise in MRI, robotics, minimally-invasive surgery, radiology, oncology and private-public transactions (IPO) to Insight Medbotics.